Literature DB >> 17337495

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.

Daniel J Drucker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17337495     DOI： 10.2337/dc07-0228

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  109 in total

1.  Chances and risks of SGLT2 inhibitors.

Authors:  Peter Mayer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-24       Impact factor: 3.000

Review 2.  Vascular repair strategies in type 2 diabetes: novel insights.

Authors:  Kira Kuschnerus; Ulf Landmesser; Nicolle Kränkel
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

Review 3.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

4.  Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.

Authors:  Michael E Widlansky; Venkata K Puppala; Tisha M Suboc; Mobin Malik; Amberly Branum; Kara Signorelli; Jingli Wang; Rong Ying; Michael J Tanner; Sudhi Tyagi
Journal:  Vasc Med       Date:  2017-02-01       Impact factor: 3.239

5.  Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Authors:  L D Carbone; P Bůžková; H A Fink; J A Robbins; M Bethel; C M Isales; W D Hill
Journal:  Osteoporos Int       Date:  2017-02-02       Impact factor: 4.507

Review 6.  The incretin system and cardiometabolic disease.

Authors:  Paul E Szmitko; Lawrence A Leiter; Subodh Verma
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

7.  The amino terminus extension in the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the active peptidase to the nucleus.

Authors:  Daniela Justa-Schuch; Ulrike Möller; Ruth Geiss-Friedlander
Journal:  Cell Mol Life Sci       Date:  2014-02-23       Impact factor: 9.261

8.  Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

Authors:  Lene Jessen; Benedikt A Aulinger; Jonathan L Hassel; Kyle J Roy; Eric P Smith; Todd M Greer; Stephen C Woods; Randy J Seeley; David A D'Alessio
Journal:  Endocrinology       Date:  2012-10-02       Impact factor: 4.736

9.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

10.  Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

Authors:  Daisuke Katagiri; Yoshifumi Hamasaki; Kent Doi; Koji Okamoto; Kousuke Negishi; Masaomi Nangaku; Eisei Noiri
Journal:  J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.